Published in Lancet on July 28, 1979
Effectiveness of amantadine in reducing relapses in multiple sclerosis. J R Soc Med (1987) 0.81
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Doctor-patient communication: the Toronto consensus statement. BMJ (1991) 8.57
SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist (2000) 6.24
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Breaking bad news: why is it still so difficult? Br Med J (Clin Res Ed) (1984) 2.81
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Myopathy, osteomalacia and hyperparathyroidism. Brain (1967) 2.11
Brain alpha-bungarotoxin binding protein cDNAs and MAbs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron (1990) 1.72
Talking to patients about cancer. BMJ (1996) 1.71
Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci (2000) 1.66
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol (2002) 1.55
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res (1997) 1.45
Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med (1997) 1.44
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol (1995) 1.43
Doctors can improve on way they deliver bad news, MD maintains. Interview by Evelyne Michaels. CMAJ (1992) 1.40
Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Ageing (1995) 1.39
Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. Ann Oncol (1992) 1.39
The real costs of emesis--an economic analysis of ondansetron vs. metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer (1993) 1.39
Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med (1990) 1.38
Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol (1990) 1.35
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer (2011) 1.31
Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults. Br J Haematol (1982) 1.30
Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry (1988) 1.28
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein. J Virol (1989) 1.27
Adaptations of glutathione antioxidant system to endurance training are tissue and muscle fiber specific. Am J Physiol (1997) 1.25
Comparative trial of volunteer and professional treatments of dysphasia after stroke. Br Med J (1979) 1.25
Monoclonal antibodies and human tumor pathology. Hum Pathol (1982) 1.24
Structure, expression, and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene (1994) 1.24
Bromocriptine in Parkinson's disease. Br J Hosp Med (1978) 1.22
Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer (2013) 1.21
Superoxide dismutase gene expression is activated by a single bout of exercise in rat skeletal muscle. Pflugers Arch (2001) 1.20
Biological characterization of human monoclonal antibodies to rabies virus. J Virol (1990) 1.20
Communicating genetic test results to the family: a six-step, skills-building strategy. Fam Community Health (2001) 1.18
Oxidative stress and aging. Role of exercise and its influences on antioxidant systems. Ann N Y Acad Sci (1998) 1.17
ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. Br J Cancer (1990) 1.17
Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol (1989) 1.15
Intrapericardial installation of bleomycin in malignant pericardial effusion. Am Heart J (1986) 1.14
The value of an improved scoring system (CGHQ) for the General Health Questionnaire in a representative community sample. Psychol Med (1988) 1.14
Intranasal apomorphine: a new treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry (1990) 1.13
Teaching medical students how to break bad news. CMAJ (1997) 1.12
Multi-disciplinary perspectives on post-partum depression: an anthropological critique. Soc Sci Med (1983) 1.11
Correlation between pterygium size and induced corneal astigmatism. Cornea (1998) 1.11
Observations on heroin and methadone withdrawal in the newborn. Pediatrics (1971) 1.10
Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet (1987) 1.09
Neurological involvement in type 1 (adult) Gaucher's disease. J Neurol Neurosurg Psychiatry (1985) 1.09
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer (2009) 1.09
Superoxide dismutase gene expression in skeletal muscle: fiber-specific adaptation to endurance training. Am J Physiol (1999) 1.08
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group. Ann Oncol (1996) 1.07
Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission. Bone Marrow Transplant (1988) 1.07
The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study. Am J Hum Genet (1999) 1.06
Transhepatic cholangiography: the radiological method of choice in suspected obstructive jaundice. Radiology (1979) 1.04
High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer (1989) 1.03
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer (2003) 1.01
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma. Br J Cancer (2004) 1.00
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer (2004) 0.99
The symptoms of patients treated for Parkinson's disease. Clin Neuropharmacol (1985) 0.99
A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol (1998) 0.99
The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br J Cancer (2006) 0.99
Who's for CPR? J R Coll Physicians Lond (1992) 0.97
Primary auditory neuropathy - an enigma. Acta Neurol Scand (2003) 0.97
Mapping of Reis-Bücklers' corneal dystrophy to chromosome 5q. Am J Ophthalmol (1996) 0.97
Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy (2011) 0.96
On the disulphide bonds of rhodopsins. Biochem J (1987) 0.95
Civil rights in a changing health care system. Health Aff (Millwood) (1997) 0.95
Normative data for lung function and exhaled nitric oxide in unsedated healthy infants. Eur Respir J (2010) 0.94
The effects of lesions in the substantia nigra. Brain (1966) 0.93
Quantitative adherence of bacteria to human corneal epithelial cells. Arch Ophthalmol (1984) 0.93
Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer (2001) 0.93
The significance of stable patients with sternal fractures. Surg Gynecol Obstet (1987) 0.92
Classification of extrapyramidal disorders. Proposal for an international classification and glossary of terms. J Neurol Sci (1981) 0.92
Detecting inertial effects with airborne matter-wave interferometry. Nat Commun (2011) 0.92
Contact B-scan echographic diagnosis of ophthalmopathic Graves' disease. J Clin Ultrasound (1975) 0.91
Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer (1996) 0.90
Phase II study of E7070 in patients with metastatic melanoma. Ann Oncol (2005) 0.90
Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2. Br J Cancer (1995) 0.89
Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies. Tumour Biol (1988) 0.89
In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res (1986) 0.89
High-dose cyclophosphamide in small-cell carcinoma of the lung. J Clin Oncol (1985) 0.89
Percutaneous diagnosis and drainage of pylephlebitis: a case report. Surgery (1987) 0.89
MRI in primary non-Hodgkin's lymphoma of the vagina associated with a uterine congenital anomaly. Br J Radiol (1997) 0.88
Elevated glial brain-derived neurotrophic factor in Parkinson's diseased nigra. Parkinsonism Relat Disord (2002) 0.88
Elimination of carcinoma cells from human bone marrow. Lancet (1982) 0.88
Muscular weakness in osteomalacia and hyperparathyroidism. J Neurol Sci (1969) 0.88
Sociocultural factors and perinatal health in a Mexican-American community. J Natl Med Assoc (1982) 0.88
A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 0.88
Does aggressive therapy improve survival in suboptimal stage IIIc/IV ovarian cancer? A Canadian-American comparative study. Gynecol Oncol (1995) 0.87
Preclamol and parkinsonian fluctuations. Clin Neuropharmacol (1993) 0.87
Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol (1996) 0.87
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer (2008) 0.87